Goodbye

Hello everyone,

Since the summer is coming to a close and the semester is almost over, I will no longer be posting any new material on my blog. I hope everyone has enjoyed all of the information I have presented and learned a lot about various topics we have covered in infectious disease as well as sickle cell disease. I have had a good time writing about these topics and hope that everyone has learned something new and found them as interesting as I have. Thank you all for taking the time to not only read, but also comment on my posts.  I hope everyone has a nice, relaxing break and I will see you again soon!
Thanks,

Eden

Hydroxyurea Treatment

Hydroxyurea was first synthesized in 1869 and is presently being used to treat a multitude of conditions, including sickle cell disease. Hydroxyurea reduces the severity of sickle cell disease by stimulation the production of fetal hemoglobin, or HbF.

HbF is the form of hemoglobin present in the fetus and small infants. Although some may persist, most HbF disappears early in childhood. Fetal hemoglobin is able to block the sickling action of red blood cells and because of this infants with sickle cell disease do not develop symptoms of the illness until HbF levels have dropped. Adults who have sickle cell disease but still retain high levels of hemoglobin F generally have a mild form of the disease.

Hydroxyurea is recommended as frontline therapy to treat adults and adolescents with moderate-to-severe recurrent pain. Hydroxyurea reduces the frequency of acute pain crises and episodes of acute chest syndrome. It is taken daily by mouth and can be taken indefinitely and the benefits appear to be long-lasting.

Not all patients respond to hydroxyurea, and the best candidates for the treatment are not yet clear. Many patients who can benefit from it are not receiving it. Hydroxyurea is still being investigated for younger patients. To date, the response to the drug in children with sickle cell disease is similar to the response in adults, and few severe adverse effects are being reported. Recent research also suggests that hydroxyurea is safe for infants.

Side effects include constipation, nausea, drowsiness, hair loss, and inflammation of the mouth. More severe side effects include reduction of white blood cells, called neutropenia, and clot-forming platelets, or thrombocytopenia. Hydroxyurea should not be taken by pregnant patients as it can cause birth defects. There have been concerns that long-term use of hydroxyurea may increase the risk of developing leukemia, but the significance of this risk remains unclear. 

Here's a case study using hydroxyurea in sickle cell disease 

Rabies Virus

The rabies virus is a bullet shaped, nonsegmented, negative stranded RNA genome that belongs to the order Mononegaviralesiruses and the Rhabdoviridae family. Rhabdoviruses are approximately 180 nm long and 75 nm wide. The rabies genome encodes five proteins: nucleoprotein, phosphoprotein, matrix protein, glycoprotein and polymerase. All rhabdoviruses have two major structural components: a helical ribonucleoprotein core and a surrounding envelope. In the ribonucleoprotein, genomic RNA is tightly encased by the nucleoprotein. Two other viral proteins, the phospoprotein and the L-protein are associated with the RNP. The glycoprotein forms approximately 400 trimeric spikes which are tightly arranged on the surface of the virus. The matrix protein is associated both with the envelope and the RNP and may be the central protein of rhabdovirus assembly. The arrangement of these proteins and the RNA genome determine the structure of the rabies virus.

When a human or animal is injected with infected saliva, the rabies virus replicates at the site of inoculation. Aided by the glycoprotein protein, the viral envelope attaches and fuses with the host cell membrane. The plasma membrane folds inside itself with clathrin-coated pits which allow cytoplasmic absorption via pinocytosis. The virions aggregate with the large endosomes, and after fusion with their membranes, they initiate the uncoating and release of the viral RNP into the cytoplasm. Since the rabies virus has a linear, single stranded RNA genome, messenger RNAs are produced to permit virus replication using the host cell machinery. Translation of the genome occurs on the free ribosomes in the cytoplasm, and some posttranslational processing occurs in the endoplasmic reticulum and golgi apparatus.

Once infected, the rabies virus travels to the brain by following the peripheral nerves. The incubation period of the disease is usually a few months in humans, depending on the distance the virus must travel to reach the central nervous system. Once the rabies virus reaches the central nervous system and symptoms begin to show, the infection is effectively untreatable and usually fatal within days.

Early-stage symptoms of rabies are malaise, headache and fever, progressing to acute pain, violent movements, uncontrolled excitement, depression, and hydrophobia. Finally, the patient may experience periods of mania and lethargy, eventually leading to coma. The primary cause of death is usually respiratory insufficiency. Overall, roughly 97% of human rabies cases result from dog bites. In the US, animal control and vaccination programs have effectively eliminated domestic dogs as reservoirs of rabies.

The real zombie virus? 

Sickle Cell Symptoms

Since sickle cell disease is a blood disorder, it has many signs and symptoms. These symptoms may present after 4 months of age. The most frequently seen symptom is anemia. Sickle cells are fragile and break apart easily and die, leaving you chronically short on red blood cells. Red blood cells usually live for about 120 days before they die and need to be replaced; but sickle cells die after only 10 to 20 days. The result is a chronic shortage of red blood cells, known as anemia. Without enough red blood cells in circulation, your body can't get the oxygen it needs to feel energized. That's why anemia causes fatigue.

Another symptom is periodic episodes of pain, called crises. Pain develops when sickle-shaped red blood cells block blood flow through tiny blood vessels to your chest, abdomen and joints. Pain can also occur in your bones. The pain may vary in intensity and can last for a few hours to a few weeks. Some people experience only a few episodes of pain while others experience a dozen or more crises a year. If a crisis is severe enough, patients may be hospitalized.

Hand-foot syndrome is another sign of sickle cell disease. Swollen hands and feet may be the first signs of sickle cell anemia in babies. The swelling is caused by sickle-shaped red blood cells blocking blood flow out of their hands and feet.

Sickle cell disease causes frequent infections. Sickle cells can damage your spleen, which fights infections, and may make you more vulnerable. Doctors commonly give infants and children with sickle cell anemia antibiotics to prevent potentially life-threatening infections, such as pneumonia.

Delayed growth is seen in sickle cell disease patients. Red blood cells provide your body with the oxygen and nutrients you need for growth and a shortage of healthy red blood cells can slow growth in infants and children and delay puberty in teenagers.

A final symptom of sickle cell disease is vision problems. Tiny blood vessels that supply your eyes may become plugged with sickle cells. This can damage the retina, which is the portion of the eye that processes visual images.

Play this word search!

Tuberculosis Treatment

Mycobacterium tuberculosis is a very slow-growing organism that requires the use of multiple drugs for several months for treatment. With the appropriate antibiotics tuberculosis can be cured in most individuals. Treatment usually combines several different antibiotic drugs that are given for at least 6 months and sometimes for as long as 12 months. However, many M. tuberculosis strains are resistant to one or more of the standard TB drugs, which complicates treatment greatly.

Currently, there are 10 drugs approved by the U.S. Food and Drug Administration for the treatment of TB. Of the approved drugs, isoniazid, rifampin, ethambutol, and pyrazinamide are considered first-line antituberculosis agents. These four drugs form the foundation of initial courses of therapy.

Drug-resistant TB is major problem for the treatment of the disease. Multidrug-resistant TB, is defined as disease caused by TB bacilli resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs. Mulitdrug-resistant tuberculosis is resistant to drugs but its resistance can be intensified by inconsistent or partial treatment. When patients do not take all their medication regularly for the required time period, drug-resistant bacteria can arise. While drug-resistant TB is generally treatable, it requires extensive chemotherapy with second-line anti-TB drugs. These second line drugs produce more severe adverse drug reactions more frequently than the preferred first line drugs. There are six classes of second-line drugs used for the treatment of TB including aminoglycosides, fluoroquinolones, polypeptides, thioamides, cycloserine, and p-aminosalicylic acid. 

Within the last few years a new form of TB has emerged, extensively drug-resistant TB. Whereas regular TB and even multidrug-resistant TB progress relatively slowly, extensively drug-resistant TB progresses much more rapidly and can be fatal within months or even a few weeks. Extensively drug-resistant TB is defined as TB that has developed resistance to at least rifampin and isoniazid, as well as to any member of the fluoroquinolone family and at least one of the aminoglycosides or polypeptides. The emergence of extensively drug-resistant TB, particularly in settings where many TB patients are also infected with HIV, poses a serious threat to TB control.

Currently, short course Direct Observation Therapy (DOTS) is a key component of the World Health Organization's campaign to stop TB. DOTS involves patient case management by trained health professionals who ensure that the patient is taking their TB drugs. Because TB has such a long course of treatment, many patients stop their medications prematurely. DOTS sends health professionals to the patient to ensure they are taking the medication and may also supply the medicine to the patient. In some areas, patients come to the DOT clinic instead of the health worker traveling to them. Often, DOTS provides enablers or incentives to ensure patients continue their treatment, such as transportation or free meals. 

History and Discovery

Although sickle cell disease has been present in Africa for over five thousand year, the first documented case of sickle cell disease in the United States occurred in 1910. Walter Clement Noel, a dental student from the island of Grenada studying in Chicago, went to Dr. James B. Herrick with symptoms of anemia and episodes of pain. Herrick, a cardiologist, did not show much interest in the case and assigned a resident, Dr. Ernest Irons, to look farther into Noel’s condition. When microscopically examining Noel’s blood, Irons discovered red cells he described as "having the shape of a sickle". This regained the attention of Herrick who became interested in the discover of a potential new, unknown disease. He consequently published a paper in a medical journal and used the term "sickle shaped cells".

　

As more cases began to surface it was clear that, for whatever reason, it occurred only or primarily in persons of African origin. In 1927, Hahn and Gillespie discovered that red blood cells from people with the disease could be made to sickle by removing oxygen. The trouble was that there were people whose red cells had this trait of sickling when deprived of oxygen but who did not have the disease. This condition became known as "sickle trait".

　

In 1949, two articles appeared independently showing conclusively that sickle cell disease was inherited and that people with sickle trait were heterozygous for the gene whereas people with the disease were homozygous. One was published by a military doctor in what was then known as Portuguese East Africa, now Mozambique, named Col. E. A. Beet. His article was in an African medical journal. The other was by Dr. James V. Neel, Chairman and founder of the Department of Human Genetics at the University of Michigan. Neel published his article in the prestigious American Journal of Science. As a result of the much wider readership of that journal, Neel usually gets the credit for the discovery although most authors are careful to cite both and many people think that Neel and Beet worked together.

　

Two years later, in 1951, the famous Nobel Prize-winning chemist, Dr. Linus Pauling and his colleague Dr. Harvey Itano, discovered that the red, oxygen-carrying protein, hemoglobin, had a different chemical structure in people with sickle cell disease. The details of the abnormality were worked out by Dr. Vernon Ingram in 1956. In the 1970’s, more details of how this abnormal structure affects the red blood cells were revealed and better tests for the detection of the disease were developed. In the years following, better ways of treating sickle cell patients and potential treatments appeared. The life span and the quality of life of patients were improved. Genetic counseling became an important tool for informing people about the risks of having a child with sickle cell disease. The goal of a total cure has not been reached but great progress has been made.

Antibiotic Replacement?

Since bacteria are ever changing and evolving, many have become resistant to the antibiotics that were originally developed to treat the infections that they cause. With more and more bacteria developing resistance faster than new antibiotics can be developed, previously treatable infections may become more serious. Bacteriophages and phage therapy may provide a solution to antibiotic resistant antibiotics.

Bacteriophages are viruses that invade bacterial cells and disrupt bacterial metabolism and cause the bacterium to lyse. Phage Therapy uses lytic bacteriophages to treat pathogenic bacterial infections. Bacteriophages do not generally cover as wide a range of bacteria as antibiotics. Most phages are specific for one species of bacteria and many are only able to lyse specific strains within a species. Because phages can be so specific, phage therapy results in less harm to the normal body flora than commonly used antibiotics, which often disrupt the normal gastrointestinal flora and result in opportunistic secondary infections by organisms such as Clostridium difficile. 

Bacteria also develop resistance to phages, but it is much easier to develop new phages than new antibiotics. A new phage may be obtained for a new strain of resistant bacteria in a few weeks compared to a few years for the development of a new antibiotic. As bacteria evolve and become resistant, the corresponding phages naturally evolve alongside. Phages have special advantage for localized use because they penetrate deeper as long as the infection is present, rather than decrease rapidly in concentration below the surface like antibiotics. The phages stop reproducing once the specific bacteria they target is destroyed and do not develop secondary resistance. With the increasing incidence of antibiotic resistant bacteria and a deficit in the development of new classes of antibiotics to counteract them, there is a need to apply phages in a range of infections.

Here is a case study describing an effective phage treatment 

Sickle Cell Disease Treatment

Presently, there is no proven cure for sickle cell disease. Bone marrow transplants are currently being considered as a potential cure, but research and experiments are still in progress. Treatment for sickle cell mainly involves the management and prevention of symptoms.

Various medications are often used for the treatment of sickle cell symptoms. Antibiotics, mainly penicillin, are prescribed for children between the ages of 2 months and 5 years to prevent pneumonia and other infections. Immunizations may also be effective in preventing infections in children. Pain relieving medications are prescribed as well as hydroxyurea to reduce the frequency of pain and may even reduce the need for blood transfusions. Hydroxyurea stimulates the production of fetal hemoglobin which in turn helps prevent the formation of sickle cells. This drug is no frequently used because it increases the risk for infections and may cause tumors or leukemia in certain situations.

Blood transfusions are also an option when helping to control sickle cell disease. Blood transfusions increase the number of normal red blood cells in the circulation and help to relieve anemia and decrease the risk of stroke. Although there are many benefits to blood transfusions, regularly transfused patients have a risk of heart, liver, and other organ damage due to the build up of excess iron in the body. Medication may be prescribed to reduce the excess levels of iron if the problem persists.

Bone marrow transplants are only recommended for patients with significant symptoms and problems from sickle cell disease. Healthy bone marrow from a donor replaces the marrow affected by sickle cell disease. The diseased marrow is first depleted by radiation or chemotherapy and the healthy stem cells are filtered from the blood of the donor and injected into the bloodstream of the patient with the disease. These healthy cells migrate to the bone marrow cavities where they begin producing new blood cells. This procedure is not used often due to the scarcity of donors, lengthy hospital stays, and possible rejection of the transplant.

This video shows a bone marrow aspiration.

See what's in you lens solution?

It is estimated that about 36 million Americans wear contact lenses. While contacts are effect at helping people see, there is also a chance that contacts and their cleaning solutions can lead to eye infections. The two most common eye infections are conjunctivitis and keratitis; which is caused by the bacteria Staphylococcus aureus and Pseudomonas aeruginosa.

Keratitis is an infection of the clear, round dome that covers the iris and pupil called the cornea. It causes pain, reduced vision, sensitivity to light and discharge from the eye. Bacterial keratitis usually develops very quickly and can cause blindness if left untreated. This type of infection may be superficial and only affect the top layers of the cornea, or deep and may leave scars. It is estimated that 30,000 people in the US are affected annually by bacterial keratitis. Contact lens wearers are at the greatest risk because contaminated lens solution and overnight contact wear are the biggest risk factors for acquiring the bacteria. 

For the diagnosis of keratitis, corneal ulcer scrapings are obtained and cultured onto chocolate, sheep blood, and Sabouraud agar. Samples of the eyelids, conjunctiva, contact lens cases, and lens solution may also be plated. Cotton swabs are not recommended because they contain fatty acids which may inhibit the growth of the bacteria. Once diagnosed, bacterial keratitis is treated with the antibiotics moxifloxacin and gatifloxacin.

Bacterial keratitis is easily preventable. Contact lens wearers should:

ALWAYS

• Wash hands properly with soap and water and dry them before handling contact lens, contact lens solutions or related accessories.
• Cleanse and disinfect your contact lens properly according to instruction.
• Have regular check-ups by your optometrist or ophthalmologist.
• Follow the professional advice from your optometrist or ophthalmologist.
• Take off the contact lens whenever you feel discomfort or redness and seek your optometrist's or ophthalmologist's advice.
• Seek medical advice from your doctor promptly if symptoms (redness, pain, blurring of vision or photophobia) persist despite removal of contact lens.

NEVER

• Wet your lens with saliva, tap water or bottled water.
• Wear your lens while swimming, taking shower, using hot tub or sauna.
• Sleep with your lens on.
• Wear them beyond the recommended period.  

Malarial Resistance

Each year, malaria affects about 400 million people, with a death rate of two to three million. Since the malarial parasite is constantly changing, and effective vaccine has yet to be developed. The sickle cell gene mutation has been shown to have an effective resistance to the malarial parasite for carriers of the gene. Carriers for the sickle cell trait have one sickle cell gene and one normal hemoglobin gene.

The sickle hemoglobin has been shown to impair malaria growth and development because of the change in the hemoglobin. Sickle cell trait does not provide complete protection against the parasite but those infected with P. falciparum are more likely to survive the acute illness. Most of this protection occurs between 2-16 months of life. This relationship was initially discovered when a correlation was found between the distribution of the gene for hemoglobin S and the distribution of malaria in Africa.

In a normal environment, the red cells of people with sickle cell remain normal and only sickle when venous oxygen levels are low. P. falciparum reduces the oxygen tension within the red cells to very low levels when it carries out its metabolism and causes the cells to sickle more readily. The deforming of these cells makes them a target for destruction by phagocytes and they are removed form the circulation and destroyed. The selective sickling of the infected cells reduces the parasite population in people with sickle cell and puts them at a greater chance to survive acute infections caused by malarial parasites. The CDC has determined that the sickle cell trait provides 60% protection against overall mortality caused by malaria.

Do You Want Flies With That?

The Fourth of July is coming up soon which means celebrations with fireworks and cookouts. While we all know to be careful with fireworks, eating outdoors may also be a cause for concern. Shigella sp is a bacteria that causes bacterial dysentery and is transmitted by feces, fingers, food, and even flies. Food left uncovered outdoors can be very enticing to flies. These flies may breed in infected feces and then contaminate the uncovered food.

Shigella spp are divided into four sup groups including S. dysenteriae, S. flexneri, S. boydii, and S. sonnei. S. sonnei is the most common group found in North America and causes around 14,000 cases of shigellosis each year.This bacteria is so potent that even the ingestion of as few as 10-100 organisms can cause an infection. Symptoms include high fever, chills, abdominal cramps, and pain and appear 1-2 days after ingestion while dysentery results after 1-3 days when the bacteria migrate from small intestine to the colon. Shigellosis is short lived with infections lasting from 5-7 days and most people affected are not hospitalized. Most patients that are hospitalized are elderly or children younger than two. Even if an infected person is asymptomatic, they can still spread Shigella sonnei to other persons.

S. sonnei is a gram negative, nonmotile, bacilli that closely resembles E. coli. Although it is resistant to many antibiotics, S. sonnei may be treated with ampicillin, trimethoprim/sulfamethoxazole , nalidixic acid, ciprofloxacin.

Prevention of Shigella sonnei can be easily resolved by hand washing, proper food preparation, and proper food storage. People should wash their hands before eating or preparing food and meat should be cooked at the proper temperature to ensure that any bacteria is killed. When outside, food should be covered so flies cannot come into contact and contaminate it. 

Commonly used methods for sickle cell disease screening

There are many different methods for screening for sickle cell disease. Then two most commonly used methods are isoelectric focusing and high performance liquid chromatography.

In isoelectric focusing, proteins are separated based on their specific isoelectric point. This point is determined by the pH in which the protein has no charge and does not migrate farther down the electric field. The specimen is added to a polyacrylamide gel attached to an electrical field and migrates from cathode to anode. The typical analytical run time for one test of ten samples to complete is 2.5 hours. The results are seen as sharp bands in their respective isoelectric points and are automatically calculated to show the percentages of each type of hemoglobin detected. Isoelectric focusing provides clearer banding patterns which are not affected by the analyte degrading in the blood spots. Because this method is not automated, the testing process is labor intensive and time consuming.

High performance liquid chromatography is ten times more expensive than isoelectric focusing. In this method, unknown hemoglobins are identified by comparing their retention times against a standard calibration curve. Test runs were considered normal with the presence of peaks in the zones representing HbF and HbA. Although variants are distinct, the presence of HbS in a specimen may interfere with the accurate HbA₂ measurement which identifies β-thalassemia. In a recent study, automated high performance liquid chromatography was calculated to have a coefficient of variation between 0.9-1.8% for the precision of retention times and a coefficient of variation of 4.4-17.5% for the precision of quantification. The retention times were shown to be within 0.01 minutes of the specified identification window. The results of this study showed this method to be an accurate and precise assay for the detection of abnormal hemoglobins.


Check out this journal article for more information

Confusing bacteria

Arcanobacterium haemolyticum is a gram positive rod with a matchbox or Chinese letter orientation. It was first discovered and described in 1946 in servicemen and people from the South Pacific. When plated out, the colony is small with a narrow zone of beta hemolysis and pits the agar. This organism has been a topic of controversy due to its resemblance to Corynebacterium pyogenes; because of this resemblance, A. haemolyticum was originally classified within the Corynebacterium genus with the subspecies hominis. Since this bacteria resembles Streptococcus pyogenes, the two are often confused and can be differentiated by the gram stain, inverse CAMP, and catalase reaction. This confusion was later resolved in 1982 when a new genus was created and this organism was renamed. The genus Arcanobacterium means secretive bacteria and is based on the characteristics of its fatty acid, peptidoglycan, and DNA.
Arcanobacterium haemolyticum typically infects teenagers and young adults aged 15 to 25 and is usually found in immunocompromised people. It is transmitted person to person through respiratory droplets and is found in the pharynx as well as the skin but there are no known risk factors. This bacteria causes pharyngitis, tonsillitis, and cellulitis. A rash believed to be caused by an exotoxin may be seen on the chest, abdomen, neck, and extremities in 20-25% of cases and can lead to diagnostic errors. The most common symptoms associated with A. haemolyticum are sore throat, pruritus, fever, pharyngeal erythema, and a nonproductive cough.

Arcanobacterium haemolyticum is usually treated with erythromycin, clindamycin, gentamicin, or cephalosporins. Serious infections may be treated with parenteral antimicrobial drugs.

Play this word search!

Introduction to Sickle Cell

Sickle cell disease is one of the most common monogenic diseases in the world with an approximated 7% of the world heterozygous carriers resulting in 300,000 newborns with severe hemoglobinopathies. It is an autosomal blood disease that causes the sickling of red blood cells. This sickle shape can lead to the development of cerebrovascular disease as well as cognitive impairment in children. If left untreated, it may also result in damage to organs such as the brain, kidneys, lungs, bones, and cardiovascular system. The sickling of red cells is caused at the sixth codon for the beta globin gene where glutamine is substituted for valine and has 900 different variants, most of which are not clinically significant. The sickling of these cells occurs due to a mutation in the hemoglobin gene and affects the ability of the hemoglobin to bind and release oxygen. This mutation results in crystallization that produces a polymer nucleus which grows and fills the cells, in turn disrupting the flexibility of the cell and causing dehydration. This can lead to a number of various complications, including a shortened life expectancy.

Sickle cell disease occurs in approximately 1 out of every 2500 newborns with black and Hispanic infants representing the majority. In infants, HbF is the major gene involved in determining the severity of the disease. Individuals who presented with a higher level of HbF generally had milder symptoms and fewer complications. Diagnosis of this disorder is based on the determination of variants of hemoglobin. Several newborn screening methods are currently being practiced; mainly isoelectric focusing and high performance liquid chromatography.

Check out this video for an animation of the sickle cell mutation in the blood.

Sick of the dorms

College can be a huge turning point in your life. New friends, new responsibilities, and new living accommodations. It can be very easy to get sick of the dorms, but it is even easier to get sick IN the dorms. One might assume that a terrible roommate is the biggest concern when moving into close quarters with other people, but airborne bacteria are actually far more serious. 

This week in lab, we isolated and identified bacteria from cerebrospinal fluid. My patient was a college student who presented with stiff neck and a petechial rash. He was said to be toxic, drowsy, and disoriented. 

These symptoms could be associated with almost any college student around exam time, but after several tests, he was found to have the bacteria Neisseria meningitides. Neisseria meningitides is the most common bacteria to cause bacterial meningitis in college aged students and the infection was most likely due to the close contact in the dormitories and could have been acquired from respiratory droplets from other asymptomatic carriers. The source of the infection is the bacteria in the nasopharynx and into the meninges. The bacteria then gain access into the CSF and cause inflammation in the subarachnoid space. Neisseria meningitides may lead to sepsis, organ damage, and even death; therefore treatment must be administered as quickly as possible after diagnosis. Penicillin is the preferred treatment option for confirmed cases of N. meningitides.  

Luckily, this disease is preventable with the proper vaccine. This vaccine is effective against 80% of the bacteria that cause meningitis and lasts about the same amount of time one spends in college. This is just one more way to prevent sickness in the dorms and ensure a happy, healthy college life.

Check out this brochure for information on the vaccine 

Welcome

Hello. My name is Eden Bray and this is my infectious diseases blog. Throughout the year I will be posting information regarding the current topics in class. For my first post,  I'll tell you a little bit about me. I'm from a small town in Kentucky and have been in Alabama a little less than a year. I received my Bachelor's degree in Chemistry from Kentucky Wesleyan College in Owensboro where I was also a member of the softball team. I'm currently enrolled in the Master's program for Clinical Laboratory Sciences at the University of Alabama at Birmingham. Some of my posts this year will about my graduate project, sickle cell disease. I hope you enjoy reading.